<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 19, 1999
LIFECELL CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware 01-19890 76-0172936
(State Or Other (Commission (IRS Employer
Jurisdiction Of File Number) Identification No.)
Incorporation) ........................................................
One Millennium Way
Branchburg, New Jersey 08876
---------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (908) 947-1100
<PAGE>
Item 5. Other Events.
On November 22, 1999, LifeCell Corporation issued the press release
attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press release dated November 22, 1999.
-2-
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LIFECELL CORPORATION
By: /s/ Fenel Eloi
---------------------------
Fenel Eloi
Senior Vice President
Date: November 22, 1999
-3-
<PAGE>
Contact: Fenel Eloi
Chief Financial Officer
LifeCell Corporation
908/947-1100
For Immediate Release
- ---------------------
LIFECELL COMPLETES PRIVATE PLACEMENT
BRANCHBURG, NJ (November 22, 1999): LifeCell Corporation (Nasdaq: LIFC) today
announced the completion of a private equity financing of 925,000 shares of the
company's common stock for a total of approximately $4 million. The shares were
purchased by a single investor, The Tail Wind Fund Ltd., a worldwide investor in
emerging growth companies and were priced at $4.20 per share. The transaction
included the issuance of 200,000 warrants priced at a 30 percent premium to the
purchase price. Representatives of Ladenburg Thalmann & Co. Inc. acted as
advisors to LifeCell for the transaction.
Paul Thomas, LifeCell president and Chief Executive Officer said, "We are
confident that with the growing sales of our current products, AlloDerm(R) and
Repliform(TM), and the planned introduction of Micronized AlloDerm(TM), this
financing will provide LifeCell with sufficient funds to achieve our stated goal
of profitability in the year 2000 while maintaining our robust Research &
Development pipeline."
LifeCell Corporation is a bioengineering company engaged in the development and
commercialization of tissue regeneration and cell preservation products.
LifeCell's tissue processing technology produces an acellular tissue matrix that
provides a complete template for normal tissue regeneration. The company's first
commercial products are: AlloDerm(R), which serves the plastic reconstructive,
dental and burns markets and Repliform(TM) which serves the urogynecology
market. In addition, the Company's current product development programs include
Micronized AlloDerm(TM), initially for the plastic reconstructive and
dermatology markets, and NeoDura(TM) for the duraplasty market. LifeCell's other
product development programs include ThromboSol(TM), a formulation for extending
the shelf life of transfusable platelets, and technologies to enhance the
storage of red blood cells, granulocytes and stem cells. For additional
information about the Company, visit LifeCell's web site at
http://www.LifeCell.com.
Certain of the statements contained in this news release are forward-looking
statements. While these statements reflected the company's current beliefs, they
are subject to uncertainties and risks that could cause actual results to differ
materially. These factors include, but are not limited to, the uncertainty of
product development, of clinical trials, of regulatory approval and of patent
protection; the demand for the Company's products and services; uncertainty
regarding the adequacy of the financing and profitability; economic and
competitive conditions and products; and other risks detailed in the Company's
Annual Report on Form 10-K/A for the year ended Dec. 31, 1998.
###
